Early research has demonstrated that CDC20 is highly expressed in multiple tumors, and is related to the poor prognosis of patients with gastric cancer, liver cancer, bladder cancer, colon cancer [34], and NSCLC [35]. This evidence concerns the gene CDC20 and urinary bladder carcinoma.